Before trial initiation, researchers from the polyclinics including the family doctors, nurses, pharmacists, and site coordinators were trained in good clinical practices and received courses on lung cancer, immunotherapy, and cancer vaccines, particularly on CIMAvax-EGF mechanism of action, safety, and efficacy. This evidence concerns the gene EGF and lung cancer.